Placeholder for clinical news, RWE and papers on Enstilar concomitant usage with other actives and/or as an adjunct therapy with biologics / systemics
Would you like to connect with LEO Pharma?
FIND OUT FIRST
Register to access to the latest developments, data, resources and offerings from LEO Pharma
GOT A REQUEST?
Email your questions or requests directly to LEO Pharma.
References:
1.Koo J, et al. J Dermatolog Treat 2016;27(2):120-127.
2.Enstilar® Australian Product Information 22-March-2022
3.https://www.pbs.gov.au/medicine/item/11091r
4.Data on File: LEO90100 – 003 MAR 2016
5.Paul C, Stein Gold L, Cambazard F et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol 2017;31;119-26.
6.Warren R et al. Poster 10348 presented at the 74th AAD Conference; Washington DC, USA, 4–8 March 2016.
7.Savary J et al. JEADV 2005; 19(Suppl. 3): 14-17
ACCESS PRODUCT INFORMATION:
ACCESS CONSUMER MEDICAL INFORMATION:
LEO Pharma Pty Ltd, ABN 72 147 880 617, Brisbane, QLD 4005. Enstilar®, Daivobet® LEO and LEO/lion device are registered trademarks of LEO Pharma A/S. ©Copyright 2022. Prepared April 2022. MAT-55769